WuXi Biologics Retains Top MSCI ESG Rating Under New Evaluation Model

For the fourth consecutive year, Shanghai-based WuXi Biologics has secured an AAA rating from MSCI, maintaining its position in the firm’s ESG Selection Indexes. This achievement arrives under the newly implemented 2026 Model 5.0, a rigorous update that triggered rating shifts for nearly 37% of all monitored corporate issuers.

Today, 10:29· Corp and Tech· 465 reads

WuXi Biologics Retains Top MSCI ESG Rating Under New Evaluation Model

The company’s sustained performance is rooted in core areas including product safety, human capital development, corporate governance, and climate strategy. CEO Chris Chen noted that the recognition validates the firm’s ongoing efforts to integrate sustainability into its Green CRDMO solutions, helping global partners meet their own environmental and social commitments throughout the value chain.

Beyond the MSCI designation, the company has accumulated a broad portfolio of sustainability credentials. These include the EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability World and Emerging Markets indexes, and an A-List status from CDP across water, climate, and supplier engagement categories. As of April 2026, the organization supports 982 integrated client projects, utilizing its global workforce of 13,000 to scale biologics production while maintaining these ESG benchmarks.

WuXi Biologics Retains Top MSCI ESG Rating Under New Evaluation Model

Comments (0)